The sustain release version of Methylphenidate is more slowly but as extensively absorbed as in the regular tablets. In a general dose of Ritalin SR tablet, there is a white to the off-white, round, biconvex, beveled edge, film-coated tablet, containing 20 mg of methylphenidate that imprinted with CIBA on one side and 16 on the other side in black ink. Doses above 60 mg daily are not recommended. The medical professional should inform about the side effects like increased heart rate, blood pressure, slurred speech, feeling more excitement, numbness, slurred speech, Slowed growth (height and weight) in children, etc.
Ritalin SR is indicated in the treatment of Attention-Deficit/Hyperactivity Disorder in children aged 6 years or older. Ritalin is indicated as part of a comprehensive treatment program that typically includes psychological, educational, and social measures and is aimed at stabilizing children with a behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional ability, and impulsivity.
Ritalin is contraindicated also in patients known to be hypersensitive to the drug, in patients with glaucoma, and in patients with motor tics or with a family history or diagnosis of Tourette’s syndrome. Ritalin is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result).